VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Published on December 13, 2013 at 7:35 AM · No Comments

VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health Sciences Center at San Antonio . The primary investigator is medical oncologist Tyler Curiel, M.D., MPH and is based on the research of Dr. M. Karen Newell-Rogers, PhD VG Life Sciences, Inc.'s Chief Scientific Advisor.

The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals. VG Life Sciences, Inc. holds the use patent for this combination treatment.

The study is reporting two clinical responses in cohort 3: disease stabilization in a patient with metastatic ovarian cancer for 4 months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. Further test information and data will be forthcoming.

"This is significant news", said John Tynan, President and CEO of VG Life Sciences, Inc. "The special characteristics of triple negative breast cancer make this unique application noteworthy."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post